Sigilon Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Sigilon Therapeutics

14/03/2023 20:56

* Sigilon Therapeutics Inc  SGTX.OQ  reported a quarterly
adjusted
loss of 21 cents​​ per share for the quarter ended in December.
The mean expectation of five analysts for the quarter was for a
loss of 38 cents per share.
    * Revenue rose 32.9% to $2.64 million from a year ago;
analysts
expected $2.67 million. 
    * Sigilon Therapeutics Inc's reported EPS for the quarter
was a
loss of 21 cents​.
    * The mean earnings estimate of analysts had risen by
about 3.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Sigilon Therapeutics Inc shares had risen by 101.1% this
quarter.
    * The company reported a quarterly loss of $6.69 million.
    * Wall Street's median 12-month price target for Sigilon
Therapeutics Inc is $2.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 14 at 08:56 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.38          -0.21          Beat
 Sep. 30 2022      -0.42          -0.27          Beat
 Jun. 30 2022      -0.43          -0.44          Missed
 Mar. 31 2022      -0.33          -0.43          Missed